Advertisement
U.S. markets open in 21 minutes
Advertisement

CytoDyn Inc. (CYDY)

Other OTC - Other OTC Delayed Price. Currency in USD
0.1710+0.0189 (+12.43%)
At close: 03:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.1521
Open0.1655
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1570 - 0.1750
52 Week Range0.1500 - 0.4800
Volume7,686,402
Avg. Volume1,241,640
Market Cap159.227M
Beta (5Y Monthly)0.20
PE Ratio (TTM)N/A
EPS (TTM)-0.0800
Earnings DateJan 05, 2024 - Jan 09, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CYDY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CYTODYN INC
    VIR: What does Argus have to say about VIR?VIR BIOTECHNOLOGY INC has an Investment Rating of SELL; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO

    VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Jacob Lalezari as interim CEO, effective November 17, 2023. Dr. Lalezari will be responsible for leading the Company’s corporate and product development, with a focus on short-term clinical development and related fundraising

  • GlobeNewswire

    November 2023 Letter to Shareholders

    VANCOUVER, Washington, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Dear Shareholders, We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the Company. Throughout our history, CytoDyn has made great strides in developing leronlimab from a single indication molecule into a platform molecule with the potential for multiple therapeutic indications. Through CytoDyn’s investment in clinical trials, we have generated valuable data demonstrating h

  • GlobeNewswire

    CytoDyn Announces Company Updates and Investment Community Update Webcast

    Claim Filed in Former CRO Litigation for Damages Exceeding $100M Dr. Arman Returns from Medical Leave as SVP of Business Operations Webcast to be held Monday, July 24th, 2023, at 1 PM PT / 4 PM ET VANCOUVER, Washington, July 11, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has filed a supplemental Sta